Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.68 |
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | MPO | P05164 | 2/20 | 0.68 |
| ▸ | HTR1D | P28221 | 10/20 | 0.67 |
| ▸ | HTR1B | P28222 | 8/20 | 0.67 |
| ▸ | HTR2B | P41595 | 3/20 | 0.65 |
| ▸ | HTR7 | P34969 | 3/20 | 0.65 |
| ▸ | HTR5A | P47898 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.65 |
| ▸ | HTR3B | O95264 | 2/20 | 0.65 |
| ▸ | HTR1E | P28566 | 2/20 | 0.65 |
| ▸ | HTR1F | P30939 | 2/20 | 0.65 |
| ▸ | HTR3A | P46098 | 2/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633081 | 0.83 | HTR1A (0.70) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL4055413 | 0.83 | HTR1A (0.70) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL1750785 | 0.81 | SLC6A4 (0.83) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL2615142 | 0.81 | MPO (1.00) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL2615141 | 0.81 | MPO (1.00) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL25380394 | 0.81 | SLC6A4 (0.83) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| Bufotenine SCHEMBL518028 | 0.81 | HTR2C (1.00) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL517473 | 0.81 | SLC6A4 (0.83) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL29471382 | 0.81 | SLC6A4 (0.83) | HTR1ASLC6A4HTR2AHTR2CMPO | |
| SCHEMBL29904417 | 0.81 | MPO (1.00) | HTR1ASLC6A4HTR2AHTR2CMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730124-A4 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORP (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1730124-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Amphora Discovery Corporation (US) | 2006-12-13 | — | — | EP | claimed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | claimed |
| WO-2005097758-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-10-20 | — | — | WO | claimed |
| CN-102264395-A | Liquid pharmaceutical compositions comprising a triptan compound and xylitol | — | 2011-11-30 | — | — | CN | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | HTR1A 3298/4885SLC6A4 1556/4885HTR2A 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.